μλ§νλ μΌμ°μΌ
**μλ§νλ(Amantadine)**μ μλ μΈν루μμ Aμ μλ°© λ° μΉλ£λ₯Ό μν νλ°μ΄λ¬μ€μ λ‘ κ°λ°λμμΌλ, νλ μμνμμλ μ£Όλ‘ **NMDA(N-λ©νΈ-D-μμ€νλ₯΄νΈμ°) μμ©μ²΄ κΈΈνμ **λ‘μμ νΉμ±μ νμ©ν©λλ€. μ£Όμ μμ μ μ© λΆμΌλ λ€μκ³Ό κ°μ΅λλ€: * **보쑰 μ§ν΅μ **: μ£Όλ‘ κ°μ κ³ μμ΄μμ λ§μ±, μ κ²½λ³μ¦μ± λλ μ€νΌμ€μ΄λ λ΄μ± ν΅μ¦(μ: μ€μ¦ 골κ΄μ μΌ, 골μ‘μ’ )μ μΉλ£νλ λ° μ¬μ©λ©λλ€. λ¨λ μ§ν΅μ λ‘λ ν¨κ³Όκ° κ±°μ μμ§λ§, NSAID, μ€νΌμ€μ΄λ λλ κ°λ°νν΄κ³Ό λ³μ©ν λ μ€μΆ κ°μ(central sensitization)μ μ΅μ νλ λ° νμν ν¨κ³Όλ₯Ό λ°νν©λλ€. * **λ§ μΈν루μμ**: λ§-2ν μΈν루μμ λ°μ΄λ¬μ€μ λν΄ μ°κ΅¬λμμΌλ, λμ λΉμ©, λΆκ·μΉν 경ꡬ ν‘μμ¨, μ λ§₯ ν¬μ¬ μ λ°μ μν λ±μΌλ‘ μΈν΄ μμμ μ¬μ©μ μ νμ μ λλ€. > **μμ ν΅μ¬**: μλ§νλμ μ κ²½κ³κ° ν΅μ¦ μ νΈμ κ³Όλ―Όν΄μ§λ 'μμΈλμ (wind-up) ν΅μ¦'(μ΄μ§ν΅ λ° ν΅κ°κ³Όλ―Ό)μ μΉλ£νλ λ° λ§€μ° μ€μν μ½λ¬Όμ λλ€.
μμ© κΈ°μ : Amantadine has distinct mechanisms depending on the therapeutic target: * **Analgesia (NMDA Antagonism)**: Chronic pain causes excessive release of excitatory neurotransmitters (glutamate and aspartate). These bind to the **NMDA receptor** on postsynaptic neurons in the dorsal horn of the spinal cord. Amantadine acts as a non-competitive antagonist, blocking the open ion channel of the **NMDA receptor** β prevents calcium (Ca2+) influx β reduces central sensitization and "wind-up" pain. * **Antiviral**: Interferes with the **influenza A virus M2 transmembrane protein** β blocks the uncoating of the virus particle and prevents viral replication. * **Antiparkinsonian (Human)**: Potentiates dopaminergic neurotransmission in the CNS and exhibits mild anticholinergic activity.
λλ¬Ό μ’ λ³ μ©λ
- Osteoarthritis pain when NSAIDs alone are not effective Β· 3-5 mg/kg PO once daily in addition to an NSAID Β· PO Β· q24h Β· Meloxicam at approved doses was used for this study.
- Adjunctive therapy for chronic pain Β· 3-5 mg/kg PO once daily Β· PO Β· q24h
- To decrease wind-up Β· 3-5 mg/kg PO once daily for one week Β· PO Β· q24h Β· 1 week
- Analgesia (adjunct for chronic pain) Β· 3-5 mg/kg Β· PO Β· sid to bid Β· Chronic Β· Potentiates the effects of other analgesics. Often combined with NSAIDs.
- Adjunctive therapy for chronic pain Β· 3 mg/kg PO once daily Β· PO Β· q24h Β· May be useful addition to NSAIDs; has not been evaluated for toxicity. May need to be compounded.
- Adjunctive therapy for chronic pain Β· 3-5 mg/kg PO once daily Β· PO Β· q24h
- Adjunctive therapy for chronic pain Β· 3 mg/kg PO once daily Β· PO Β· q24h
- Analgesia (adjunct for chronic pain) Β· 3-5 mg/kg Β· PO Β· sid Β· Chronic Β· Liquid formulations may be bitter and difficult to administer.
- Acute treatment of equine-2 influenza Β· 5 mg/kg IV q4h Β· IV Β· q4h Β· Not commonly used due to expense, PK variability, and seizure risk.
μ©λμ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μ°Έκ³ μλ£μ λλ€. νμ μ΅μ λΌλ²¨κ³Ό κ°λ³ νμμ λν΄ νμΈνμμμ€.
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Known hypersensitivity to amantadine or rimantadine
- Untreated angle-closure glaucoma
- Extra-label use in chickens, turkeys, and ducks (Prohibited by FDA)
μ΄μλ°μ
- Agitation or restlessness (especially early in therapy)
- Loose stools, flatulence, or diarrhea
- Narrow safety margin in cats (potential for neurotoxicity)
- Seizures (reported in horses given IV)
μ½λ¬Ό μνΈμμ©
- Anticholinergic drugs Β· May enhance the anticholinergic effects of amantadine.
- CNS Stimulants (e.g., selegiline) Β· Concomitant use may increase the CNS stimulatory effects of amantadine.
- Trimethoprim/sulfa, quinidine, quinine, thiazide diuretics, triamterene Β· May decrease the renal excretion of amantadine, yielding higher and potentially toxic blood levels.
- Urinary acidifiers (e.g., methionine, ammonium chloride, ascorbic acid) Β· May increase the renal excretion of amantadine, potentially decreasing its efficacy.
- Trimethoprim/Sulfamethoxazole Β· Decreased renal clearance of amantadine, potentially leading to toxicity Β· moderate
- Anticholinergics Β· Increased anticholinergic side effects (e.g., dry mouth, urine retention) Β· minor
- CNS stimulants Β· Increased risk of agitation, restlessness, or seizures Β· moderate
λͺ¨λν°λ§
- Adverse effects (especially GI upset and agitation/behavioral changes)
- Clinical efficacy (reduction in pain scores, improved mobility)
κ³Όμ©λ
Overdoses are potentially very serious due to a fairly narrow therapeutic index. * **Cats**: Toxic dose reported is 30 mg/kg. Behavioral effects may be noted at 15 mg/kg. * **Dogs**: Behavioral effects noted at 15 mg/kg. * **Humans**: Overdoses as low as 2 grams have been fatal. Signs include cardiac dysfunction (arrhythmias, hypertension, tachycardia), pulmonary edema, CNS toxicity (tremors, seizures, psychosis, agitation, coma), hyperthermia, and renal dysfunction. **Treatment**: No specific antidote. Empty the gut if possible. Provide intensive monitoring and supportive therapy. Forced urine acidifying diuresis may increase renal excretion. Physostigmine has been suggested for cautious use in treating CNS effects.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.